The rates of miscarriages and major congenital malformations after exposure to biologics during pregnancy do not deviate from these rates in the general population.

It is likely that use of adalimumab, certolizumab pegol, and etanercept is safe during pregnancy.

Data on risks of using abatacept, anakinra, canakinumab, golimumab, rituximab, tocilizumab, ustekinumab, and vedolizumab are scarce.